In this issue:
OS analysis from SOC-1 trial of surgery for relapsed disease
HIPEC during cytoreduction for recurrent disease prolongs survival
PRIMA: No survival benefit to niraparib maintenance
HRd status is not predictive of cediranib/olaparib activity
CA-125 is not a reliable surrogate for progression during PARP inhibition
Survival benefit to pembrolizumab + chemoradiotherapy in cervical cancer
Adjuvant pembrolizumab/chemo may benefit dMMR endometrial cancer
Simple hysterectomy may be an option for early-stage cervical cancer
LACC confirms open surgery as the gold standard approach for cervical cancer
Please login below to download this issue (PDF)